The COVID-19 pandemic brought the term "Polymerase Chain Reaction testing" into the mainstream. The PCR method is a type of nucleic acid amplification test (NAAT) that detects a pathogen by finding ...

C1q is the initiating component of the classical complement pathway and plays a critical role in activating macrophages and microglia through receptor-mediated signaling. Dysregulated C1q activity ...

Thank you, Eva, and thank you all for joining us this morning. Before turning to our fourth quarter results, I would like to ...

Formal process to evaluate ‘Stage 1' financing strategy in parallel with DFSHIGHLIGHTSDefinitive Feasibility Study ...

Quantum computers—devices that process information using quantum mechanical effects—have long been expected to outperform classical systems on certain tasks. Over the past few decades, researchers ...

Hi InnovatorBench team, thanks for creating a benchmark that tries to capture longer timescales and more realistic innovation workflows. It is refreshing to see something beyond short single shot ...

Suchandrima Bhowmik has written over 300 articles on various health conditions, medical news, and recent breakthroughs. Her work appears in several publications, including Medical News Today, ...

Carrie Madormo, RN, MPH, is a health writer. She has over a decade of experience as a registered nurse, practicing in a variety of fields, such as pediatrics, oncology, chronic pain, and public health ...

According to the American Cancer Society, colorectal cancer is the second leading cause of cancer death. Enrichment of regulatory T cells (T-regs) in solid cancers is generally associated with poor ...

The complement system is an innate immune response that leads to increased inflammation. The drug pegcetacoplan—a complement inhibitor—was approved for medical use in the United States in 2021 to ...

Detailed mapping of CD4⁺ T cells from children with systemic lupus erythematosus (SLE) has revealed distinct immune cell subsets with likely roles in disease pathogenesis, according to a study led by ...

Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...